Edap Tms SA (ADR)  

(Public, NASDAQ:EDAP)   Watch this stock  
Find more results for EDAP
3.15
-0.08 (-2.48%)
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.12 - 3.25
52 week 1.15 - 6.05
Open 3.21
Vol / Avg. 27,395.00/91,500.00
Mkt cap 80.77M
P/E     -
Div/yield     -
EPS -0.20
Shares 24.96M
Beta 1.95
Inst. own 16%
May 13, 2015
Q1 2015 Edap Tms SA Earnings Call
May 12, 2015
Q1 2015 Edap Tms SA Earnings Release
Apr 2, 2015
Q4 2014 Edap Tms SA Earnings Call
Apr 1, 2015
Q4 2014 Edap Tms SA Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -39.25% -1.91%
Operating margin -10.00% -6.48%
EBITD margin - -3.12%
Return on average assets - -1.73%
Return on average equity - -4.19%
Employees 161 -
CDP Score - -

Address

Parc Activite La Poudrette Lamartine 4/6 Rue du Dauphine
VAULX-EN-VELIN, 69120
France
+33-4-72153150 (Phone)
+33-4-72153151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EDAP TMS S.A. is engaged in developing and marketing the Ablatherm device, an advanced choice for intensity focused ultrasound (HIFU) treatment of localized prostate cancer. The Company operates two divisions: HIFU and urology devices and services (UDS) (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases HIFU treatment is shown to be a minimally invasive treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. It is also used for patients who failed a radiotherapy treatment.

Officers and directors

Philippe Chauveau Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Marc Oczachowski Chief Executive Officer and Director
Bio & Compensation  - Reuters
Eric Soyer Chief Financial Officer
Bio & Compensation  - Reuters
Pierre Beysson Independent Director
Bio & Compensation  - Reuters
Robrecht L.W. Michiels Independent Director
Bio & Compensation  - Reuters
Argil J. Wheelock M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters